Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

NewsGuard 100/100 Score

Immunomedics Inc. (Nasdaq:IMMU) today announced that clinical trial results from the Phase IIb EMBLEM™ study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy.

The title of the presentations, followed by a link to the posters presented, are listed below:

SOURCE Immunomedics Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows potential for universal flu vaccine with broad antibody response